Fig. 5.

Treatment with H6F notably increased the frequency of CD8⁺CD25⁺Foxp3⁺ T cells in NOD.β2m^null.HHD mice. Spleen-, pancreatic lymph node (PLN)-, inguinal lymph node (ILN)- and pancreas-infiltrating (PIL) cells were freshly isolated from the indicated peptide-treated nondiabetic NOD.β2m^null.HHD mice at the age of 12 weeks (n = 8–16). a The percentages of CD8⁺CD25⁺ T cells and CD8⁺CD25⁺Foxp3⁺ T cells in the spleen and PLNs were determined by flow cytometry. The data are expressed as the mean ± SD. b Comparison of the frequencies of CD8⁺CD25⁺ and CD8⁺CD25⁺Foxp3⁺ T cells in ILNs, PLNs, and spleens from H6F-treated nondiabetic NOD.β2m^null.HHD mice (n = 8). The data are expressed as the mean ± SD. c Representative FACS plots showing the frequencies of CD8⁺CD25⁺ and CD8⁺CD25⁺Foxp3⁺ T cells among PIL cells pooled from four nondiabetic NOD.β2m^null.HHD mice with the indicated peptide treatments. d Comparison of the frequencies of CD8⁺CD25⁺Foxp3⁺ T cells among PIL cells and PLNs from the same group of NOD.β2m^null.HHD mice treated with mIns1B_5-14 or H6F (n = 16). The results of the PIL cells are expressed as the mean ± SD (n = 4, each sample derived from pooled pancreatic infiltrating cells from four mice), and the PLN results are expressed as the mean ± SD (n = 16). Significance was determined by the Mann–Whitney test